New York, USA, March 04, 2025 (GLOBE NEWSWIRE) -- BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight BALVERSA (erdafitinib) has strong market potential in ...

Friday afternoon, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application (sNDA) for Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial ...

The FDA amended its approval for Balversa for the treatment of patients with locally advanced or metastatic bladder cancer. The Food and Drug Administration (FDA) approved Balversa (erdafitinib) for ...

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said. The recent approval of Balversa (erdafitinib) ...

10 urothelial cancer patients in Scotland are anticipated to receive this treatment per year [i] High Wycombe, UK (12 May 2025) – Johnson & Johnson is delighted to announce that BALVERSA® (erdafitinib ...

Johnson & Johnson’s (J&J) Balversa (erdafitinib) has been granted approval by the European Commission (EC) to treat a subset of bladder cancer patients. The pan-fibroblast growth factor receptor (FGFR ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved erdafitinib for certain adults with locally advanced or metastatic urothelial carcinoma. The ...

This approval updates the previous indication which received accelerated approval in 2019. The Food and Drug Administration (FDA) has approved Balversa (erdafitinib) for the treatment of adult ...

DUBLIN--(BUSINESS WIRE)--The "Balversa - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Balversa - Drug Insight, 2019 report provides comprehensive information of the ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...